---
title: "Oriental Remedies & Herbals Ltd (526989) — Share Price, Financials & Analysis"
symbol: "526989"
company: "Oriental Remedies & Herbals Ltd"
canonical: "https://tapetide.com/stocks/526989"
bse_code: "526989"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
generated_at: "2026-09-13T19:38:50.930Z"
---

# Oriental Remedies & Herbals Ltd (526989)

Canonical page: https://tapetide.com/stocks/526989

## Company

- **BSE Code:** 526989
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** orhl.in

## Latest Price

## Key Insights

### Strengths

- Company is almost debt free.

### Weaknesses

- Company has low interest coverage ratio.

## Growth Rates

| Metric | 1Y |
| --- | --- |
| net income growth | 0% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2024 | Mar 2025 | Sep 2025 |
| --- | --- | --- | --- |
| Sales | 84 | 110 | 138 |
| Expenses | 76 | 78 | 106 |
| Operating Profit | 8 | 32 | 31 |
| OPM % | 10 | 29 | 23 |
| Other Income | 0 | 1 | 2 |
| Interest | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 |
| Profit before tax | 8 | 31 | 31 |
| Tax % | 31 | 26 | 24 |
| Net Profit | 5 | 23 | 24 |
| EPS in Rs | — | 18.2 | 13.78 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2011 | Mar 2012 |
| --- | --- | --- |
| Sales | 0 | 0 |
| Expenses | 0.01 | 0.01 |
| Operating Profit | -0.01 | -0.01 |
| Other Income | 0 | 0 |
| Interest | 0 | 0 |
| Depreciation | 0 | 0 |
| Profit before tax | -0.01 | -0.01 |
| Tax % | 0 | 0 |
| Net Profit | -0.01 | -0.01 |
| Dividend Payout % | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2011 | Mar 2012 |
| --- | --- | --- |
| Equity Capital | 3.12 | 3.12 |
| Reserves | -1.78 | -1.79 |
| Borrowings | 0 | 0 |
| Other Liabilities | 0.03 | 0.04 |
| Total Liabilities | 1.37 | 1.37 |
| Fixed Assets | 0 | 0 |
| CWIP | 0 | 0 |
| Investments | 0.25 | 0.25 |
| Other Assets | 1.12 | 1.12 |
| Total Assets | 1.37 | 1.37 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2011 | Mar 2012 |
| --- | --- | --- |
| Cash from Operating Activity | -0.01 | -0.01 |
| Cash from Investing Activity | 0 | 0 |
| Cash from Financing Activity | 0 | 0 |
| Net Cash Flow | -0.01 | -0.01 |
| Free Cash Flow | -0.01 | -0.01 |
| CFO/OP | 100 | 100 |

### Ratios

| Item | Mar 2011 | Mar 2012 |
| --- | --- | --- |
| ROCE % | — | -0.75 |

## Shareholding Pattern

### annual

| Category | Dec 2025 |
| --- | --- |
| Promoters | 32.47% |
| FIIs | 2.15% |
| DIIs | 1.21% |
| Public | 64.16% |
| No. of Shareholders | 2545 |

### Quarterly

| Category | Sep 2025 | Dec 2025 |
| --- | --- | --- |
| Promoters | 32.47% | 32.47% |
| FIIs | 2.59% | 2.15% |
| DIIs | 3.21% | 1.21% |
| Public | 61.73% | 64.16% |
| No. of Shareholders | 2368 | 2545 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Sell
- **Buy / Neutral / Sell:** 3 / 7 / 9

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 29.62 | Buy |
| EMA (10) | 29.86 | Buy |
| SMA (20) | 30.17 | Sell |
| EMA (20) | 29.93 | Sell |
| SMA (50) | 29.78 | Buy |
| EMA (50) | 30.23 | Sell |
| SMA (100) | 31.66 | Sell |
| EMA (100) | 30.95 | Sell |
| SMA (200) | 32.33 | Sell |
| EMA (200) | 33.23 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 49.82 | Neutral |
| MACD (12,26,9) | -0.07 | Sell |
| Stochastic (14,3,3) | 40.5 | Neutral |
| ADX (14) | 16.22 | Neutral |
| Williams %R (14) | -64.38 | Neutral |
| ATR (14) | 2.09 | High Volatility |
| ROC (12) | -4.99 | Sell |
| Stoch RSI (14) | 36.92 | Neutral |
| UO (7,14,28) | 56.36 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 3 February 2026 - Investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written … | [Price movement 3 February 2026 - Investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written …](https://www.nseindia.com/companies-listing/corporate-filings-announcements?symbol=FLYSBS&tabIndex=sme) |
| 24 January 2026 - Investor presentation filed for Jan 24, 2026 call; FY24 revenue ₹106.49 Cr, fleet expansion planned. | [Investor Presentation 24 January 2026 - Investor presentation filed for Jan 24, 2026 call; FY24 revenue ₹106.49 Cr, fleet expansion planned.](https://nsearchives.nseindia.com/corporate/FLYSBS_24012026013445_InvestorPresentation.pdf) |
| 24 January 2026 - Analyst and investor Zoom call on 24 Jan 2026; attendee list provided; no UPSI. | [Analysts/Institutional Investor Meet/Con. Call Updates 24 January 2026 - Analyst and investor Zoom call on 24 Jan 2026; attendee list provided; no UPSI.](https://nsearchives.nseindia.com/corporate/FLYSBS_24012026193700_Outcomeofinvestorcall.pdf) |
| 13 February 2026 - CARE report for quarter ended Dec 31, 2025 on FlySBS IPO (Rs102.53cr); minor sub-head deviations, Rs16.29cr unutilized. | [Monitoring Agency Report 13 February 2026 - CARE report for quarter ended Dec 31, 2025 on FlySBS IPO (Rs102.53cr); minor sub-head deviations, Rs16.29cr unutilized.](https://nsearchives.nseindia.com/corporate/FLYSBS_13022026184049_MAReport.pdf) |
| 12 February 2026 - Approved monitoring report for quarter ended Dec 31, 2025; KRMM appointed internal auditor FY2025-26; recommended S.A.E. secretarial auditors. | [Outcome of Board Meeting 12 February 2026 - Approved monitoring report for quarter ended Dec 31, 2025; KRMM appointed internal auditor FY2025-26; recommended S.A.E. secretarial auditors.](https://nsearchives.nseindia.com/corporate/FLYSBS_12022026230716_Outcome.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:38:50.930Z.